Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 60, Issue 5, 2005, Pages 693-696

  Oldhoff, J M ^a   Darsow, U ^b   Werfel, T ^c   Katzer, K ^b   Wulf, A ^c   Laifaoui, J ^b   Hijnen, D J ^a   Plotz S ^b   Knol, E F ^a   Kapp, A ^c   Bruijnzeel Koomen, C A F M ^a   Ring, J ^b   De Bruin Weller, M S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Anti IL 5; Atopic dermatitis; Eosinophils; Mepolizumab; TARC

Indexed keywords

FLUTICASONE PROPIONATE; INTERLEUKIN 5; MEPOLIZUMAB; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EOSINOPHIL; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PATHOGENESIS; PHYSICIAN GLOBAL ASSESSMENT OF IMPROVEMENT SCORE; PRIORITY JOURNAL; PRURITUS SCORE; RANDOMIZED CONTROLLED TRIAL; SCORING ATOPIC DERMATITIS SCORE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; CHEMOKINES, CC; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 20244375866     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2005.00791.x     Document Type: Article

References (17)

1. Eisner J, Forssmann U. Another renaissance of eosinophils in allergic diseases. ACI Int 2002;14:151-155.
2. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992;79:3101-3109.
3. Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995;182:1169-1174.
4. Warringa RA, Mengelers HJ, Kuijper PH, Raaijmakers JA, Bruijnzeel PL, Koenderman L. In vivo priming of platelet-activating factor-induced eosinophil chemotaxis in allergic asthmatic individuals. Blood 1992;79:1836-1841.
5. Uings I, McKinnon M. Development of 1L-5 receptor antagonists. Curr Pharm Des 2002;8:1837-1844.
6. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144-2148.
7. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199-204.
8. Buttner C, Lun A, Splettstoesser T, Kunkel G, Renz H. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 2003;21:799-803.
9. Leiferman KM. A role for eosinophils in atopic dermatitis. J Am Acad Dermatol 2001;45(1 Suppl.):S21-S24.
10. Wedi B, Raap U, Lewrick H, Kapp A. Delayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J Allergy Clin Immunol 1997;100:536-543.
11. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980;92:44-47.
12. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10-19.
13. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001;107:535-541.
14. Hijnen D, Bruin-Weller M, Costing B, Lebre C, De Jong E, Bruijnzeel-Koomen C et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK.) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004;113:334-340.
15. Beck LA, Dalke S, Leiferman KM, Bickel CA, Hamilton R, Rosen H et al. Cutaneous injection of RANTES causes eosinophil recruitment: comparison of nonallergic and allergic human subjects. J Immunol 1997;159:2962-2972.
16. Rothenberg ME. Eosinophilia. N Engl J Med 1998;338:1592-1600.
17. Kay AB, Menzies-Gow A. Eosinophils and interleukin-5: the debate continues. Am J Respir Crit Care Med 2003;167:1586-1587.